patient subgroup...
age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr beta variant (B.1.351 / 501Y.V2, South Africa) delta variant (B.1.617.2, Indian) elderly (typically over 65yr) positive for SARS-Cov-2 at baseline
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
Janssen AD26 vaccine (JNJ-78436735) - versus potential COVID-19 treatments - for COVID-19 prophylaxis (excluding children)
pdf
xlsx
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 deaths 0.19 [0.04, 0.81]< 1 0% 1 study (1/-) 98.7 % NA not evaluable crucial - hospitalization 1.25 [0.04, 42.33]< 1 93% 2 studies (1/1) 45.2 % low not evaluable high important - symptomatic Covid-19 0.33 [0.27, 0.41]< 1 0% 1 study (1/-) 100.0 % NA not evaluable important - severe COVID-19 occurrence 0.32 [0.19, 0.54]< 1 28% 2 studies (1/1) 100.0 % serious not evaluable low non important - safety endpoints 00 ATE (Myocardial infarction or ischemic stroke) 0.50 [0.12, 2.00]< 1 0% 1 study (1/-) 83.6 % NA not evaluable non important - deep vein thrombosis 3.00 [0.61, 14.86]< 1 0% 1 study (1/-) 9.0 % NA not evaluable non important - Guillain-Barré syndrome 1.00 [0.06, 15.98]< 1 0% 1 study (1/-) 50.0 % NA not evaluable non important - intracranial hemorrhage 1.61 [0.63, 4.15]< 1 0% 2 studies (-/2) 16.1 % NA not evaluable non important - ischemic stroke 1.06 [0.66, 1.72]< 1 0% 3 studies (1/2) 40.4 % NA not evaluable non important - Myocardial infarction 1.71 [1.15, 2.55]< 1 0% 5 studies (3/2) 0.4 % NA not evaluable non important - myocarditis 5.11 [0.70, 37.23]< 1 0% 1 study (-/1) 5.5 % NA not evaluable non important - pericarditis 2.00 [0.07, 59.60]< 1 0% 1 study (1/-) 34.7 % NA not evaluable non important - pulmonary embolism 0.81 [0.24, 2.82]< 1 19% 4 studies (2/2) 62.7 % NA not evaluable non important - serious adverse events (SAE), any 1.53 [0.25, 9.36]< 1 0% 1 study (1/-) 32.3 % NA not evaluable non important - venous thromboembolism 2.67 [0.90, 7.89]< 1 0% 2 studies (2/-) 3.8 % some concern not evaluable moderate non important - AE of interest endpoints 00 cerebral venous sinus thrombosis (CVST) 2.00 [0.07, 59.60]< 1 0% 1 study (1/-) 34.7 % NA not evaluable important - appendicitis 1.20 [0.37, 3.93]< 1 0% 1 study (1/-) 38.2 % NA not evaluable non important - Bell's palsy 1.50 [0.25, 8.98]< 1 0% 1 study (1/-) 32.9 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.